Adenovirus-mediated herpes simplex virus type-1 thymidine kinase gene therapy suppresses oestrogen-induced pituitary prolactinomas.
Adenovirus-mediated herpes simplex virus type-1 thymidine kinase gene therapy suppresses oestrogen-induced pituitary prolactinomas.
复制标题
腺病毒介导的单纯疱疹病毒 1 型胸苷激酶基因治疗可抑制雌激素诱导的垂体催乳素瘤。
DOI:
10.1210/jcem.85.3.6482
复制
发表时间:
2000
期刊:
影响因子:
--
通讯作者:
M. G. Castro
中科院分区:
文献类型:
--
作者:
S. Windeatt;T. Southgate;Ricardo A. Dewey;Federico Bolognani;M. Perone;A. Larregina;T. Maleniak;I. Morris;R. G. Goya;D. Klatzmann;P. Lowenstein;M. G. Castro
We tested the hypothesis that gene transfer using recombinant adenovirus vectors (RAds) expressing herpes simplex virus type 1 thymidine kinase (HSV1-TK) might offer an alternative therapeutic approach for the treatment of pituitary prolactinomas that do not respond to classical treatment strategies. HSV1-TK converts the prodrug ganciclovir (GCV) to GCV monophosphate, which is in turn further phosphorylated by cellular kinases to GCV triphosphate, which is toxic to proliferating cells. One attractive feature of this system is the bystander effect, whereby untransduced cells are also killed. Our results show that RAd/HSV1-TK in the presence of GCV is nontoxic for the normal anterior pituitary (AP) gland in vitro, but causes cell death in the pituitary tumor cell lines GH3, a PRL/GH-secreting cell line, and AtT20, a corticotrophic cell line. We have used sulpiride- and oestrogen-induced lactotroph hyperplasia within the rat AP gland as an in vivo animal model. Intrapituitary infection of rats bearing oestrogen-induced lactotroph hyperplasia, with RAd/ HSV1-TK and subsequent treatment with GCV, decreases plasma PRL levels and reduces the mass of the pituitary gland. More so, there were no deleterious effects on circulating levels of other AP hormones, suggesting that the treatment was nontoxic to the AP gland in situ. In summary, our results show that suicide gene therapy using the HSV1-TK transgene could be further developed as a useful treatment to complement current therapies for prolactinomas.
登录
查看更多内容
DOI:
10.1016/0026-0495(91)90111-9
发表时间:
1991
期刊:
Metabolism: clinical and experimental
影响因子:
--
作者:
Adler,RA;Krieg,RJ;Farrell,ME;Deiss,WP;MacLeod,RM
通讯作者:
MacLeod,RM
DOI:
10.1210/jcem.81.6.8964885
发表时间:
1996-06
期刊:
The Journal of clinical endocrinology and metabolism
影响因子:
--
作者:
Andrew Freese;M. During;B. Davidson;T. Gennarelli;M. Kaplitt;E. Flamm;P. Snyder
通讯作者:
Andrew Freese;M. During;B. Davidson;T. Gennarelli;M. Kaplitt;E. Flamm;P. Snyder
DOI:
--
发表时间:
1996
期刊:
Journal of andrology.
影响因子:
--
作者:
Awoniji,CA;Roberts,D;Chandrashekar,V;Hurst,BS;Tucker,KE;Schlaff,WD
通讯作者:
Schlaff,WD
影响因子:
4.1
作者:
Bartke,A;Doherty,PC;Steger,RW;Morgan,WW;Amador,AG;Herbert,DC;Siler-Khodr,TM;Smith,MS;Klemcke,HG;Hymer,WC
通讯作者:
Hymer,WC